News
INM
0.3030
+10.99%
0.0300
InMed Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/644,484 Titled "Metabolic Engineering Of E. Coli For The Biosynthesis Of Cannabinoid Products"
Benzinga · 15h ago
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply in today's pre-market trading following first-quarter results. Tesla posted weaker-than-expected earnings and sales results for its first quarter on Tuesday. The electric vehicle giant also announced plans to speed up the launch of new models. Chicken Soup for the Soul Entertainment shares gained 49.4% in pre- market trading.
Benzinga · 23h ago
Weekly Report: what happened at INM last week (0415-0419)?
Weekly Report · 2d ago
Inmed Pharmaceuticals Inc: Current report
Press release · 5d ago
InMed Pharmaceuticals Strengthens Alzheimer’s Program with New Expert
TipRanks · 6d ago
InMed Pharmaceuticals Welcomes Alzheimer’s Expert
TipRanks · 6d ago
InMed Pharmaceuticals Preclinical Success with INM-089
TipRanks · 04/16 18:52
InMed Pharmaceuticals Provides Update On INM-089 In The Treatment Of Dry Age-Related Macular Degeneration; Small Molecule Drug Acting As A Preferential Signaling Ligand For CB1/CB2
Benzinga · 04/16 18:42
INMED PHARMACEUTICALS INC - SMALL MOLECULE DRUG ACTING AS A PREFERENTIAL SIGNALING LIGAND FOR CB1/CB2
Reuters · 04/16 18:41
InMed’s INM-089 Shows Promise for AMD Treatment
TipRanks · 04/16 12:49
Weekly Report: what happened at INM last week (0408-0412)?
Weekly Report · 04/15 12:26
Weekly Report: what happened at INM last week (0401-0405)?
Weekly Report · 04/08 12:32
InMed Pharmaceuticals Excites with Alzheimer’s Breakthrough
InMed Pharmaceuticals (INM) has revealed promising pre-clinical results for a potential Alzheimer's treatment. The company is working on a new drug called INM-901 to treat Alzheimer's disease. The drug could be a significant step forward in the treatment of the disease.
TipRanks · 04/05 15:42
InMed’s INM-901 Shows Promise Against Alzheimer’s
Inmed Pharmaceuticals Inc. Has announced promising preclinical results for INM-901, a potential treatment for Alzheimer’s disease. The treatment shows reduced neuroinflammation and improved neuronal function. INM is a potential candidate for the treatment of Alzheimer's disease.
TipRanks · 04/04 12:37
Weekly Report: what happened at INM last week (0325-0329)?
Weekly Report · 04/01 12:28
Weekly Report: what happened at INM last week (0318-0322)?
Weekly Report · 03/25 12:32
InMed Pharmaceuticals Granted Nasdaq Compliance Extension
TipRanks · 03/20 17:52
InMed Pharmaceuticals Receives Nasdaq Extension
TipRanks · 03/20 13:08
InMed Pharmaceuticals gets 180-Day extension to regain compliance with Nasdaq
InMed Pharmaceuticals gets 180-Day extension to regain compliance with Nasdaq. The company has been granted an additional 180-day compliance period until September 16, 2024. The Nasdaq has no immediate effect on the listing or trading of the company's shares. Healthcare InMed pharmaceuticals Inc. (INM)
Seeking Alpha · 03/20 12:38
Weekly Report: what happened at INM last week (0311-0315)?
Weekly Report · 03/18 12:30
More
Webull provides a variety of real-time INM stock news. You can receive the latest news about Inmed Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About INM
InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its segments include InMed Pharmaceuticals and BayMedica. The InMed Pharmaceuticals segment is engaged in research and development of cannabinoid-based pharmaceutical products. The BayMedica segment is focused on developing manufacturing technologies to produce rare cannabinoids for sale in the health and wellness industry. Its two product candidates include INM-755 and INM-088. INM-755 is developed as a topical skin cream formulation containing cannabinol (CBN) for the treatment of symptoms related to Epidermolysis Bullosa (EB). INM-088 is used for the treatment of glaucoma.